


# Squamous Cell Carcinoma of the Anal Canal: Disease State Overview

MI-DIS-US-0104 04/25

FOR MEDICAL INFORMATION PURPOSES ONLY. NOT FOR PROMOTIONAL USE. DO NOT COPY, DISTRIBUTE OR OTHERWISE REPRODUCE.


# **Table of Contents**





# **Disease Epidemiology and Etiology**

# Anal Cancer is a Cancer of The Lower GI Tract




GI, gastrointestinal; SCAC, squamous cell carcinoma of the anal canal.

1. Shridhar R, et al. CA Cancer J Clin. 2015;65:139–62. 2. American Cancer Society. Accessed Jan 2025. https://www.cancer.org/cancer/anal-cancer/about/what-is-anal-cancer.html.

3. National Cancer Institute. Accessed Jan 2025. https://www.cancer.gov/types/anal/patient/anal-treatment-pdq. Lower Gastrointestinal Anatomy 2022; ©2022 Terese Winslow LLC, U.S. Govt. has certain rights. 4. Symer MM, Yeo HL. F1000Research. 2018;7:F1000 Faculty Rev-1572.



### **Risk Factors for Anal Cancer**



#### HPV Infection is the Strongest Risk Factor for Anal Cancer<sup>1</sup>


HPV, human papilloma virus; HIV, human immunodeficiency virus.

1. Anal Cancer Foundation. Accessed Jan 2025. <u>https://www.analcancerfoundation.org/anal-cancer/what-is-anal-cancer/hpv-cancer</u>. 2. Silva Dalla Libera L, et al. *J Oncol*. 2019;2019:6018269. 3. Wang CJ, et al. *Surg Oncol Clin N Am*. 2017;26:17–31. 4. Shridhar R, et al. *CA Cancer J Clin*. 2015;65:139-162. 5. Krzyowska-Firych J, et al. *J Infect Public Health*.2019:12:1-6. 6. Daling J, et al. *Cancer*. 2004;101:270-280.



# **Risk Factors for Anal Cancer: HPV Infection**

#### HPV is the common tumor-initiating event in SCAC, cervical cancer, and HNSCC





Incyte

HNSCC, head and neck squamous cell carcinoma.

1. Centers for Disease Control and Prevention. Accessed Jan 2025. <u>https://www.cdc.gov/cancer/hpv/cases.html</u>. 2. Krzowska-Firych J, et al. J Infect Public Health. 2019;12:1-6.

6

# **Risk Factors for Anal Cancer: Immunosuppression**

#### Immunosuppression plays a pivotal role in the pathogenesis of anal cancer<sup>1-3</sup>

- Reduces the ability to combat viral infection and control oncogenic viral processes<sup>1</sup>
- Immunosuppression caused by organ transplant, long-term steroid use, or AIDS significantly increases risk of anal cancer, likely due to persistent HPV infection<sup>1,2</sup>
- Increases rates of anal cancer recurrence<sup>3</sup>

#### HIV infection is associated with an increased risk of HPV acquisition persistence<sup>1,4,5</sup>

- Approximately 28% of men and 1% of women with anal cancer also have HIV infection,<sup>1</sup> and risk of subsequent HPV acquisition is approximately doubled in the presence of HIV infection<sup>4</sup>
- The immunosuppression associated with HIV infection reduces the ability to control oncogenic viral processes, such as HPV-mediated cell transformation<sup>1</sup>
- HIV-RNA viral load is associated with reduced HPV clearance<sup>4,5</sup>

1. Wang CJ, et al. Surg Oncol Clin N Am. 2017;26:17–31. 2. Shridhar R, et al. CA Cancer J Clin. 2015;65:139-162. 3. Bingmer K, et al. Am J Surg. 2020;219:88-92. 4. Looker KJ, et al. J Int AIDS Soc. 2018;21:e25110. 5. Geskus RB, et al. AIDS. 2016;30:37-44.






#### Most Primary Cancers of the Anal Canal Are SCAC and Impact Older Individuals

- In 2024, the estimated number of new anal cancer cases in the US was 10,540
- Annually, there are 1.9 new cases of anal cancer per 100,000 people
  - Incidence is higher in women (2.3 per 100,000) than in men (1.6 per 100,000)
- In 2021, there were an estimated 81,779 people living with anal cancer in the United States

Rates of incidence and mortality of anal cancer are rising

Incidence	Mortality
+2.2%	+5.1%
per year	per year



SCAC, squamous cell carcinoma of the anal canal.

Surveillance, Epidemiology, and End Results Program (SEER). Accessed Jan 2025. <u>https://seer.cancer.gov/statfacts/html/anus.html</u>. Cancer Stat Facts: Anal Cancer was originally published by the National Cancer Institute - https://seer.cancer.gov/statfacts/html/anus.html [seer.cancer.gov].





# Signs, Symptoms, and Diagnosis

# **Signs and Symptoms of Anal Cancer**

#### **Important Symptoms of Anal Cancer**

- Bleeding from the rectum
- Itching in or around the rectum
- A lump or mass at the anal opening
- Pain or a feeling of fullness in the anal area
- Narrowing of stool or other changes in bowel movement
- Abnormal discharge from the anus
- Incontinence of stool (loss of bowel control)
- Swollen lymph nodes in the anal or groin areas

Bleeding from the rectum is often the first sign of disease

Anal cancer can also be asymptomatic



# **Diagnosing Anal Cancer**

staging before treatment

#### **Physical and Digital** Anoscopy<sup>1,2</sup> Endoscopy<sup>2</sup> **Rectal Examination**<sup>1,2</sup> ~45% of patients with anal carcinoma Examination of the anus and Examination of the anus and present with rectal bleeding, and lower rectum using a short, rigid rectum using an endoscope 30% have either pain or sensation of a tube called an anoscope rectal mass Chest/Abdomen CT + Pelvis CT FDG-PET/CT Scan<sup>1,2</sup> Biopsy<sup>1,2</sup> or MRI<sup>1,2</sup> Provides information on local FDG-PET/CT scan provides high Diagnosis of anal cancer is made by FNA disease extent and dissemination to sensitivity in identifying anal cancer in or excisional biopsy-proven histology other organs and is used to verify patients who have normal-sized lymph

#### Primary diagnoses are often made by gastroenterologists, colorectal surgeons, or PCPs<sup>2</sup>


nodes on CT imaging

CT, computerized tomography; FDG, fluorodeoxyglucose. FNA, fine needle aspiration; MRI, magnetic resonance imaging; PCP, primary care physician; PET, positron emission tomography.

1. Referenced with permission from the 11 Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Anal Carcinoma V.2.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. American Cancer Society. Accessed January 2025. https://www.cancer.org/cancer/anal-cancer/detection-diagnosis-staging/how-diagnosed.html.



# NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Anal Cancer: Diagnostic Workup



<sup>a</sup> The superior border of the functional anal canal, separating it from the rectum, has been defined as the palpable upper border of the anal sphincter and puborectalis muscles of the anorectal ring. It is approximately 3 to 5 cm in length, and its inferior border starts at the anal verge, the lowermost edge of the sphincter muscles, corresponding to the introitus of the anal orifice. <sup>b</sup> For melanoma histology, see the NCCN Guidelines for Melanoma: Cutaneous; for adenocarcinoma, see the NCCN Guidelines for Rectal Cancer. <sup>c</sup> CT should be with intravenous and oral contrast. Pelvic MRI with contrast. If intravenous iodinated contrast material is contraindicated due to significant contrast allergy or renal failure, then MRI examination of the abdomen and pelvis with intravenous gadolinium-based contrast agent can be obtained in select patients (see American College of Radiology contrast manual: <u>https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast\_Media.pdf</u>). Intravenous contrast is not required for the chest CT. <sup>d</sup> FDG-PET/CT scan does not replace a diagnostic CT. PET/CT performed skull base to mid-thigh.

Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Anal Carcinoma V.2.2025. © 2025 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines<sup>®</sup> and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.





# **Staging and Prognosis**

### **Anal Cancer Staging**

#### AJCC TNM Staging Classification for Anal Carcinoma

Stage	1	lla	llb
Description	≤2 cm	2-5 cm	<pre></pre>
Primary tumor (T)	T1 (≤2 cm)	T2 (2–5 cm)	T1-T2 (≤5 cm)
Regional lymph node (N)	NO	NO	N1
Distant metastasis (M)	MO	MO	MO


AJCC, American Joint Committee on Cancer; M0, no distant metastasis; N0, no regional lymph node metastasis; N1, metastasis to lymph nodes near the rectum; TMN, tumor, node, metastasis.

American Cancer Society. Accessed Jan 2025. https://www.cancer.org/cancer/types/anal-cancer/detection-diagnosis-staging/staging.html.



### Anal Cancer Staging (cont)


#### AJCC TNM Staging Classification for Anal Carcinoma



N1, nearby lymph nodes; M1, distant metastasis.

American Cancer Society. Accessed Jan 2025. https://www.cancer.org/cancer/types/anal-cancer/detection-diagnosis-staging/staging.html.

## **Anal Cancer Stage at Diagnosis and Survival Rates**



<sup>a</sup> SEER 22 (Excluding IL, MA) 2014–2020, all races, both sexes by SEER Summary Stage. <sup>b</sup> Data have been rounded to the nearest whole number. Surveillance, Epidemiology, and End Results Program (SEER). Accessed Jan 2025. <u>https://seer.cancer.gov/statfacts/html/anus.html</u>. Cancer Stat Facts: Anal Cancer was originally published by the National Cancer Institute - https://seer.cancer.gov/statfacts/html/anus.html [seer.cancer.gov].



